Jump to navigation Jump to search
Clinical data
Routes of
Oral, rectal
ATC code
Legal status
Legal status
  • S4 (Au), POM (UK), ℞-only (U.S.)
Pharmacokinetic data
Bioavailability2.4–36% (oral)
Protein binding55%
MetabolismHepatic (CYP1A2)
Elimination half-life2–4 hours
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass198.264 g/mol

WikiDoc Resources for Tacrine


Most recent articles on Tacrine

Most cited articles on Tacrine

Review articles on Tacrine

Articles on Tacrine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Tacrine

Images of Tacrine

Photos of Tacrine

Podcasts & MP3s on Tacrine

Videos on Tacrine

Evidence Based Medicine

Cochrane Collaboration on Tacrine

Bandolier on Tacrine

TRIP on Tacrine

Clinical Trials

Ongoing Trials on Tacrine at Clinical Trials.gov

Trial results on Tacrine

Clinical Trials on Tacrine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tacrine

NICE Guidance on Tacrine


FDA on Tacrine

CDC on Tacrine


Books on Tacrine


Tacrine in the news

Be alerted to news on Tacrine

News trends on Tacrine


Blogs on Tacrine


Definitions of Tacrine

Patient Resources / Community

Patient resources on Tacrine

Discussion groups on Tacrine

Patient Handouts on Tacrine

Directions to Hospitals Treating Tacrine

Risk calculators and risk factors for Tacrine

Healthcare Provider Resources

Symptoms of Tacrine

Causes & Risk Factors for Tacrine

Diagnostic studies for Tacrine

Treatment of Tacrine

Continuing Medical Education (CME)

CME Programs on Tacrine


Tacrine en Espanol

Tacrine en Francais


Tacrine in the Marketplace

Patents on Tacrine

Experimental / Informatics

List of terms related to Tacrine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Tacrine is a parasympathomimetic and a centrally acting cholinesterase inhibitor (anticholinesterase). It was the first centrally-acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease, and was marketed under the trade name Cognex. Tacrine was first synthesised by Adrien Albert at the University of Sydney.

Clinical use

Tacrine was the prototypical cholinesterase inhibitor for the treatment of Alzheimer's disease. Studies have found that it may have a small beneficial effect on cognition and other clinical measures, though adequate study data is limited and the clinical relevance of these findings is unclear.[1][2]

The use of tacrine is limited by poor oral bioavailability, the necessity for four-times daily dosing, and considerable adverse drug reactions (including nausea, diarrhea, urinary incontinence and hepatotoxicity) such that few patients could tolerate therapeutic doses.[3]

Other newer cholinesterase inhibitors, such as donepezil, are now preferred over tacrine.


As stated above, overdosage of tacrine may giva rise to severe side effects such as nausea, vomiting, salivation, sweating, bradycardia, hypotension, collapse, and colvulsions. Tertiary anticholinergics, such as atropine, may be used as an antidote for overdose.

Major form of metabolism is in the liver via hydroxylation of benzylic carbon by CYP450. This forms the major metabolite 1-hydroxy-tacrine (velnacrine) which is still active.


  1. Qizilbash N, Whitehead A, Higgins J, et al. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. JAMA 1998;280(20):1777-82. PMID 9842955
  2. Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology, 5th edition. Edinburgh: Churchill Livingstone; 2003.
  3. Sweetman S, editor. Martindale: the complete drug reference, 34th ed. London: Pharmaceutical Press; 2004. ISBN 0-85369-550-4

See also

Template:Anticholinesterases Template:Anti-dementia drugs Template:WH Template:WikiDoc Sources